Original Article
Prevalence of Osteopenia and Osteoporosis in Patients with Noncystic Fibrosis Bronchiectasis
Abstract
Objective: The objective of our study was to define the prevalence of osteoporosis and osteopenia in patients with noncystic fibrosis bronchiectasis (NCFB).Methods: We conducted a retrospective chart review of all patients with physician-diagnosed NCFB evaluated at Mayo Clinic Florida between January 1, 2011 and June 3, 2013.
Results: A total of 113 patients with physician-diagnosed NCFB and confirmatory findings on computed tomography scan were identified. The cohort was overwhelmingly women (90%) with a mean age of 72 ± 10.6 and a body mass index of 24.8 ± 6.8. The medical history indicated that 30% (34) had osteoporosis, 39% (44) had osteopenia, and 9% (10) had normal bone density. In 25 (22%) of the subjects, bone density was unknown or undocumented. Most were never smokers (55.7%) or past smokers (41.6%) and airflow obstruction was present in 58% of the 84 subjects who had undergone pulmonary function tests. In total, 57 patients (50.44%) and 45 patients (39.82%) had been prescribed proton pump inhibitors and inhaled corticosteroids, respectively. Bone mineral density testing was performed during the study period in 70 (62%) of the subjects. Decreased bone density consistent with osteoporosis was present in 19 (27%); 41 (59%) had osteopenia, and bone density was normal in 10 (14%) subjects. Diminished bone density was present in 82.8% (24/29) of patients younger than age 70, with 27.6% (8/29) having osteoporosis. There was a greater incidence of diminished bone density in those with reduced body mass index (100% vs 82%), but this difference did not reach statistical significance ( P = 0.10). Forty-seven and 32% of patients with diminished bone density were using proton pump inhibitor therapy and inhaled corticosteroids, respectively.
Conclusions: This study suggested that diminished bone density is common in patients with bronchiectasis, with >85% of this cohort having osteoporosis or osteopenia confirmed by bone density testing. Although the prevalence of both bronchiectasis and diminished bone density increases with advancing age and female sex, these data suggest a greater prevalence than expected based on demographic risks. Medications that may predispose individuals to diminished bone density are not uncommonly prescribed in patients with bronchiectasis. Provider awareness of the substantial prevalence of diminished bone density in patients with bronchiectasis may improve patient care by prompting appropriate screening for and treatment of osteoporosis and osteopenia. In light of these observations, judicious use of medications that may predispose to diminished bone density is warranted.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12:205-209.
2. Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995;108:955-961.
3. Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest 2012;142:432-439.
4. Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1991;144:914-916.
5. International Osteoporosis Foundation. Facts and statistics. www.iofbonehealth.org/facts-statistics#category. Published 2015. Accessed September 20, 2016.
6. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-1733.
7. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
8. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-947.
9. Dam TT, Harrison S, Fink HA, et al. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos Int 2010;21:1341-1349.
10. Kennedy JH. “Silent” gastroesophageal reflux: an important but little known cause of pulmonary complications. Chest 1962;42:42-45.
11. Mandal P, Morice AH, Chalmers JD, et al. Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis. Respir Med 2013;107:1008-1013.
12. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-326.
13. van der Hoorn MM, Tett SE, de Vries OJ, et al. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study. Bone 2015;81:675-682.
14. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003;114:10-14.
15. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011;66:699-708.
16. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953.
17. Moberg LM, Nilsson PM, Samsioe G, et al. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas 2014;78:310-315.
18. Chee C, Sellahewa L, Pappachan JM. Inhaled corticosteroids and bone health. Open Respir Med J 2014;8:85-92.
19. Brenckmann C, Papaioannou A, Freitag A, et al. Osteoporosis in Canadian adult cystic fibrosis patients: a descriptive study. BMC Musculoskelet Disord 2003;4:13.
20. Baker JF, Putman MS, Herlyn K, et al. Body composition, lung function, and prevalent and progressive bone deficits among adults with cystic fibrosis. Joint Bone Spine 2016;83:207-211.
21. Guran T, Turan S, Karadag B, et al. Bone mineral density in children with non-cystic fibrosis bronchiectasis. Respiration 2008;75:432-436.
22. Sunny SS, Burns A, Jary H, et al. P90 osteoporosis in non-cystic fibrosis bronchiectasis (NCFBr) adults. Thorax 2012;67:A102-A103.
23. Dave RK, Arroliga AC, Prince-Fiocco M. Osteoporosis and osteopenia in patients with non-cystic fibrosis (non-CF) bronchiectasis. Chest 2009;136 4_MeetingAbstracts :9S.
24. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Osteoporosis or Low Bone Mass at the Femur Neck or Lumbar Spine in Older Adults: United States, 2005-2008. Published 2012. Available at: www.cdc.gov/nchs/data/databriefs/db93.htm. Accessed May 8, 2016.
25. Pasco JA, Seeman E, Henry MJ, et al. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 2006;17:1404-1409.
26. Hauser B, Riches PL, Wilson JF, et al. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) 2014;53:1759-1766.
27. Crandall CJ, Yildiz VO, Wactawski-Wende J, et al. Postmenopausal weight change and incidence of fracture: post hoc findings from Women’ Health Initiative Observational Study and Clinical Trials. BMJ 2015;350:h25.
28. Villalon KL, Gozansky WS, Van Pelt RE, et al. A losing battle: weight regain does not restore weight loss-induced bone loss in postmenopausal women. Obesity (Silver Spring) 2011;19:2345-2350.
29. Compston JE, McConachie C, Stott C, et al. Changes in bone mineral density, body composition and biochemical markers of bone turnover during weight gain in adolescents with severe anorexia nervosa: a 1-year prospective study. Osteoporos Int 2006;17:77-84.
30. Loukides S, Bouros D, Papatheodorou G, et al. Exhaled H(2)O(2) in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest 2002;121:81-87.
31. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can’ they clear the infection? Respir Res 2003;4:8.
32. Liang B, Feng Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine 2012;42:190-195.
